Cancer Research AM No Date
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Schueneman, A. J.
Right arrow Articles by Hallahan, D. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schueneman, A. J.
Right arrow Articles by Hallahan, D. E.
[Cancer Research 63, 4009-4016, July 15, 2003]
© 2003 American Association for Cancer Research

Experimental Therapeutics

SU11248 Maintenance Therapy Prevents Tumor Regrowth after Fractionated Irradiation of Murine Tumor Models1

Aaron J. Schueneman, Eric Himmelfarb, Ling Geng, Jiahua Tan, Edwin Donnelly, Dirk Mendel, Gerald McMahon and Dennis E. Hallahan2

Vanderbilt University School of Medicine, Nashville, Tennessee 37232 [A. J. S., E. H.]; Departments of Radiation Oncology [L. G., J. T., D. E. H.], Radiology [E. D.], and Cancer Biology [D. E. H.], Vanderbilt University School of Medicine, Nashville, Tennessee 37232-5671; and Sugen, Inc., South San Francisco, California 94080 [D. M., G. M.]

Receptor tyrosine kinase activation contributes to cell viability during cytotoxic therapy. The novel broad spectrum receptor tyrosine kinase inhibitor, SU11248, inhibits vascular endothelial growth factor receptor 2, platelet-derived growth factor receptor, c-kit, and fetal liver tyrosine kinase 3. In this study, we maintained SU11248 plasma levels beyond the completion of radiotherapy to determine whether tumor regrowth can be delayed. The antiangiogenic effects of SU11248 were demonstrated using human umbilical vein endothelial cells in vitro. Apoptosis increased and clonogenic survival decreased when SU11248 was used in combination with radiation from 0 to 6 Gy on endothelial cells. In vivo tumor growth delay was increased in C57B6J mice with Lewis lung carcinoma or glioblastoma multiform (GL261) hind limb tumors. Mice were treated with daily i.p. injections (40 mg/kg) of SU11248 during 7 days of radiation treatment (21 Gy). Combined treatment with SU11248 and radiation significantly reduced tumor volume as compared with either treatment alone. Concomitant reduction in vasculature was confirmed using the dorsal vascular window model. The vascular length established using images taken from a consistent quadrant in the window show the combination therapy was more effective in destroying tumor vasculature than either treatment alone. SU11248 maintenance administration beyond the completion of radiotherapy results in prolongation of tumor control. In summary, SU11248 enhances radiation-induced endothelial cytotoxicity, resulting in tumor vascular destruction and tumor control when combined with fractionated radiotherapy in murine tumor models. Moreover, inhibition of angiogenesis well beyond radiation therapy may be a promising treatment paradigm for refractory human neoplasms.




This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
C. Timke, H. Zieher, A. Roth, K. Hauser, K. E. Lipson, K. J. Weber, J. Debus, A. Abdollahi, and P. E. Huber
Combination of Vascular Endothelial Growth Factor Receptor/Platelet-Derived Growth Factor Receptor Inhibition Markedly Improves Radiation Tumor Therapy
Clin. Cancer Res., April 1, 2008; 14(7): 2210 - 2219.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
L. B. Saltz, L. S. Rosen, J. L. Marshall, R. J. Belt, H. I. Hurwitz, S. G. Eckhardt, E. K. Bergsland, D. G. Haller, A. C. Lockhart, C. M. Rocha Lima, et al.
Phase II Trial of Sunitinib in Patients With Metastatic Colorectal Cancer After Failure of Standard Therapy
J. Clin. Oncol., October 20, 2007; 25(30): 4793 - 4799.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
B. M. Fenton and S. F. Paoni
The Addition of AG-013736 to Fractionated Radiation Improves Tumor Response without Functionally Normalizing the Tumor Vasculature
Cancer Res., October 15, 2007; 67(20): 9921 - 9928.
[Abstract] [Full Text] [PDF]

Home page
 Neuro OncolHome page
S. de Bouard, P. Herlin, J. G. Christensen, E. Lemoisson, P. Gauduchon, E. Raymond, and J.-S. Guillamo
Antiangiogenic and anti-invasive effects of sunitinib on experimental human glioblastoma
Neuro-oncol, October 1, 2007; 9(4): 412 - 423.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
A. M.P. Omuro, S. Faivre, and E. Raymond
Lessons learned in the development of targeted therapy for malignant gliomas
Mol. Cancer Ther., July 1, 2007; 6(7): 1909 - 1919.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
G. Giaccone
The Potential of Antiangiogenic Therapy in Non-Small Cell Lung Cancer
Clin. Cancer Res., April 1, 2007; 13(7): 1961 - 1970.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
S. Senan and E. F. Smit
Design of Clinical Trials of Radiation Combined with Antiangiogenic Therapy
Oncologist, April 1, 2007; 12(4): 465 - 477.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
P. Laakkonen, M. Waltari, T. Holopainen, T. Takahashi, B. Pytowski, P. Steiner, D. Hicklin, K. Persaud, J. R. Tonra, L. Witte, et al.
Vascular Endothelial Growth Factor Receptor 3 Is Involved in Tumor Angiogenesis and Growth
Cancer Res., January 15, 2007; 67(2): 593 - 599.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. R. Horsman and D. W. Siemann
Pathophysiologic Effects of Vascular-Targeting Agents and the Implications for Combination with Conventional Therapies
Cancer Res., December 15, 2006; 66(24): 11520 - 11539.
[Abstract] [Full Text] [PDF]

Home page
 J Ultrasound MedHome page
D. W. N. Kim, J. Huamani, K. J. Niermann, H. Lee, L. Geng, L. L. Leavitt, R. A. Baheza, C. C. Jones, S. Tumkur, T. E. Yankeelov, et al.
Noninvasive Assessment of Tumor Vasculature Response to Radiation-Mediated, Vasculature-Targeted Therapy Using Quantified Power Doppler Sonography: Implications for Improvement of Therapy Schedules.
J. Ultrasound Med., December 1, 2006; 25(12): 1507 - 1517.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
C. Cao, J. M. Albert, L. Geng, P. S. Ivy, A. Sandler, D. H. Johnson, and B. Lu
Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitor AZD2171 and Fractionated Radiotherapy in Mouse Models of Lung Cancer
Cancer Res., December 1, 2006; 66(23): 11409 - 11415.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. Tan, L. Geng, E. M. Yazlovitskaya, and D. E. Hallahan
Protein Kinase B/Akt-Dependent Phosphorylation of Glycogen Synthase Kinase-3{beta} in Irradiated Vascular Endothelium
Cancer Res., February 15, 2006; 66(4): 2320 - 2327.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
R. J. Motzer, M. D. Michaelson, B. G. Redman, G. R. Hudes, G. Wilding, R. A. Figlin, M. S. Ginsberg, S. T. Kim, C. M. Baum, S. E. DePrimo, et al.
Activity of SU11248, a Multitargeted Inhibitor of Vascular Endothelial Growth Factor Receptor and Platelet-Derived Growth Factor Receptor, in Patients With Metastatic Renal Cell Carcinoma
J. Clin. Oncol., January 1, 2006; 24(1): 16 - 24.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
B. M. Erovic, M. Pelzmann, M. Ch. Grasl, J. Pammer, G. Kornek, W. Brannath, E. Selzer, and D. Thurnher
Mcl-1, Vascular Endothelial Growth Factor-R2, and 14-3-3{sigma} Expression Might Predict Primary Response against Radiotherapy and Chemotherapy in Patients with Locally Advanced Squamous Cell Carcinomas of the Head and Neck
Clin. Cancer Res., December 15, 2005; 11(24): 8632 - 8636.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. Abdollahi, D. W. Griggs, H. Zieher, A. Roth, K. E. Lipson, R. Saffrich, H.-J. Grone, D. E. Hallahan, R. A. Reisfeld, J. Debus, et al.
Inhibition of {alpha}v{beta}3 Integrin Survival Signaling Enhances Antiangiogenic and Antitumor Effects of Radiotherapy
Clin. Cancer Res., September 1, 2005; 11(17): 6270 - 6279.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
E. T. Shinohara, L. Geng, J. Tan, H. Chen, Y. Shir, E. Edwards, J. Halbrook, E. A. Kesicki, A. Kashishian, and D. E. Hallahan
DNA-Dependent Protein Kinase Is a Molecular Target for the Development of Noncytotoxic Radiation-Sensitizing Drugs
Cancer Res., June 15, 2005; 65(12): 4987 - 4992.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
D. Zips, W. Eicheler, P. Geyer, F. Hessel, A. Dorfler, H. D. Thames, M. Haberey, and M. Baumann
Enhanced Susceptibility of Irradiated Tumor Vessels to Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibition
Cancer Res., June 15, 2005; 65(12): 5374 - 5379.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
P. E. Huber, M. Bischof, J. Jenne, S. Heiland, P. Peschke, R. Saffrich, H.-J. Grone, J. Debus, K. E. Lipson, and A. Abdollahi
Trimodal Cancer Treatment: Beneficial Effects of Combined Antiangiogenesis, Radiation, and Chemotherapy
Cancer Res., May 1, 2005; 65(9): 3643 - 3655.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
K. J. Williams, B. A. Telfer, S. Brave, J. Kendrew, L. Whittaker, I. J. Stratford, and S. R. Wedge
ZD6474, a Potent Inhibitor of Vascular Endothelial Growth Factor Signaling, Combined With Radiotherapy: Schedule-Dependent Enhancement of Antitumor Activity
Clin. Cancer Res., December 15, 2004; 10(24): 8587 - 8593.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
B. M. Fenton, S. F. Paoni, and I. Ding
Pathophysiological Effects of Vascular Endothelial Growth Factor Receptor-2-Blocking Antibody plus Fractionated Radiotherapy on Murine Mammary Tumors
Cancer Res., August 15, 2004; 64(16): 5712 - 5719.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
L. Geng, J. Tan, E. Himmelfarb, A. Schueneman, K. Niermann, A. Fu, K. Cuneo, E. A. Kesicki, J. Treiberg, J. S. Hayflick, et al.
A Specific Antagonist of the p110{delta} Catalytic Component of Phosphatidylinositol 3'-Kinase, IC486068, Enhances Radiation-Induced Tumor Vascular Destruction
Cancer Res., July 15, 2004; 64(14): 4893 - 4899.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
P. Laakkonen, M. E. Akerman, H. Biliran, M. Yang, F. Ferrer, T. Karpanen, R. M. Hoffman, and E. Ruoslahti
Antitumor activity of a homing peptide that targets tumor lymphatics and tumor cells
PNAS, June 22, 2004; 101(25): 9381 - 9386.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2003 by the American Association for Cancer Research.